• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Adagrasib provides antitumour activity against KRAS G12C mutant metastatic colorectal cancer both as monotherapy and in combination with cetuximab

byKassandra McFarlaneandSze Wah Samuel Chan
January 16, 2023
in Chronic Disease, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Overall tumour response to monotherapy treatment with adagrasib was 23% 46% in combination with cetuximab.

2. Median progression-free survival was 5.6 months on adagrasib monotherapy and 6.9 months on combination therapy with cetuximab.

Evidence Rating Level: 2 (Good)

Study Rundown: Kirsten rat sarcoma virus oncogene homologue (KRAS) is responsible for oncogenesis in almost half of the patients diagnosed with colorectal cancer (CRC). The prognosis is worse for patients with the KRAS G12C allele. The small-molecule adagrasib is a covalent inhibitor of KRAS G12C and renders it inactive. This phase 1-2 clinical trial investigated the use of adagrasib as a single-agent treatment for metastatic CRC (mCRC) with mutated KRAS G12C as well as in combination with cetuximab in heavily pre-treated patients. The primary outcome of this study was the activity of adagrasib monotherapy as determined by objective response. Secondary outcomes include progression-free survival (PFS), overall survival (OS), and the safety of the study drug. The objective response to adagrasib was 23% as compared to 46% of combination therapy patients. The median PFS was 5.6 months in the single therapy adagrasib group, whereas it was 6.9 months in the combination group. Median OS was 19.8 in the adagrasib group and 13.4 months in the combination treatment group. Adverse events (AEs) occurred in the majority of patients including 93% in the adagrasib group and 100% in the combination group. Diarrhea was a common AE between the groups, as was nausea and vomiting. Limitations to this study include that it was a non-randomized trial, which prevents directly comparing the two treatment groups and that the study enrolled small numbers of patients into each group, limiting the generalizability of the results. Overall, the results from this study provide evidence that adagrasib monotherapy and its combination with cetuximab as a treatment for pretreated mCRC with KRAS G12C mutation is a potentially useful therapy requiring further investigation.

Click to read the study in The New England Journal of Medicine

Relevant Reading: KRAS G12C metastatic colorectal cancer: specific features of a new emerging

target population.

RELATED REPORTS

Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer

In-Depth [prospective cohort]: This open-label trial was non-randomized and recruited adult patients with mCRC and KRAS G12C mutation who had received standard treatment with fluoropyrimidine-based chemotherapy, but had no further standard-of-care treatment options available at enrollment. Forty-four patients with mCRC were provided with adagrasib monotherapy, while 32 patients received a combination of adagrasib and cetuximab. Of the monotherapy group, only 43 patients were clinically evaluable, whereas only 28 of the combination group were. The activity of adagrasib was determined by the overall response to the drug. According to a blinded central review, 23% of those receiving monotherapy had a response (95% confidence interval (CI), 12-39%). The objective response to the combination therapy was 46% of the 28 patients (95% CI, 28-66%). Medium PFS in the monotherapy group was 5.6 months (95% CI, 4.1 – 8.3 months) and median OS was 19.8 months (95% CI, 12.5 – 23.0). Median PFS among all 32 combination therapy patients was 6.9 months (95% CI, 5.4 – 8.1 months) and the median OS was 13.4 months (95% CI, 9.5-20.1 months). 93% of patients in the monotherapy treatment group experienced AEs of any grade as compared to 100% of patients in combination therapy. Grade 3 and above adverse events occurred in 34% of the monotherapy arm compared to 16% in the combination arm.

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: adagrasibadvanced colorectal cancerKRAS G12C
Previous Post

High-dose selenium not associated with a reduction in morbidity and mortality in high-risk cardiac surgery patients

Next Post

Adding posterior wall isolation to pulmonary vein isolation not beneficial in ablation for patients with persistent atrial fibrillation — the CAPLA trial

RelatedReports

Oophorectomy associated with reduced cancer risk and all-cause mortality for BRCA1/2 patients
Oncology

Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer

January 9, 2023
Next Post
Patient Basics: Atrial Fibrillation

Adding posterior wall isolation to pulmonary vein isolation not beneficial in ablation for patients with persistent atrial fibrillation — the CAPLA trial

Cisplatin with Veliparib in BRCA Stratified Metastatic Triple-Negative Breast Cancer

Lisinopril and carvedilol reduce cardiotoxicity in breast cancer patients receiving trastuzumab and anthracyclines

Comparison of simulation versus didactic-based instruction for transesophageal echocardiography teaching: the SIMULATOR randomized clinical trial

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Chronic obstructive pulmonary disease associated with worse postoperative outcomes
  • Empagliflozin use is associated with slower progression of chronic kidney disease
  • Diagnostic tool may help identify cerebral palsy regardless of encephalopathy features
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options